Expression of three members of the TNF-R family of receptors (4-1BB, lymphotoxin-β receptor, and Fas) in human lung

被引:37
作者
Boussaud, V
Soler, P
Moreau, J
Goodwin, RG
Hance, AJ
机构
[1] Fac Xavier Bichat, INSERM U82, F-75878 Paris 18, France
[2] Immunex Res & Dev Corp, Seattle, WA 98101 USA
关键词
4-1BB; Fas; lymphotoxin-beta-receptor; TNF-R superfamily;
D O I
10.1183/09031936.98.12040926
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Receptors belonging to the tumour necrosis factor receptor (TNF-R) superfamily are implicated in a variety of important biological processes. Although messenger ribonucleic acid coding for many of these receptors has been detected in lung, little is known about their expression in this organ. In this study, immunohistochemical techniques were used to evaluate the expression of three receptors of this family (4-1BB, lymphotoxin-beta receptor (LT beta-R), and Fas) in normal human lung, lung carcinomas and by tuberculous and sarcoid granulomas. The 4-1BB receptor was uniformly expressed by endothelial cells of small vessels and by basal epithelial cells within pseudostratified bronchial epithelium. LTP-R expression by parenchymal cells was limited to those of epithelial origin (bronchial and bronchiolar epithelium, hyperplastic alveolar epithelium and lung carcinomas). Fas was present on both fibroblasts and epithelial cells (bronchial and alveolar epithelium and most, but not all, carcinomas), but not on endothelial cells. A subpopulation of T-lymphocytes expressed these receptors, but only Fas was detected on normal alveolar macrophages and epithelioid cells. Thus, 4-1BB, LT beta-R, and Fas have characteristic and only partially overlapping patterns of expression in the lung. The findings should facilitate further evaluation of their role in lung homeostasis and pathology.
引用
收藏
页码:926 / 931
页数:6
相关论文
共 31 条
  • [1] ABREUMARTIN MT, 1995, J IMMUNOL, V155, P4147
  • [2] MOLECULAR AND BIOLOGICAL CHARACTERIZATION OF HUMAN 4-1BB AND ITS LIGAND
    ALDERSON, MR
    SMITH, CA
    TOUGH, TW
    DAVISSMITH, T
    ARMITAGE, RJ
    FALK, B
    ROUX, E
    BAKER, E
    SUTHERLAND, GR
    DIN, WS
    GOODWIN, RG
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 1994, 24 (09) : 2219 - 2227
  • [3] REGULATION OF APOPTOSIS AND T-CELL ACTIVATION BY FAS-SPECIFIC MAB
    ALDERSON, MR
    TOUGH, TW
    BRADDY, S
    DAVISSMITH, T
    ROUX, E
    SCHOOLEY, K
    MILLER, RE
    LYNCH, DH
    [J]. INTERNATIONAL IMMUNOLOGY, 1994, 6 (11) : 1799 - 1806
  • [4] The tumor necrosis factor ligand and receptor families
    Bazzoni, F
    Beutler, B
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (26) : 1717 - 1725
  • [5] CAR1, a TNFR-related protein, is a cellular receptor for cytopathic avian leukosis sarcoma viruses and mediates apoptosis
    Brojatsch, J
    Naughton, J
    Rolls, MM
    Zingler, K
    Young, JAT
    [J]. CELL, 1996, 87 (05) : 845 - 855
  • [6] Browning JL, 1997, J IMMUNOL, V159, P3288
  • [7] Signaling through the lymphotoxin beta receptor induces the death of some adenocarcinoma tumor lines
    Browning, JL
    Miatkowski, K
    Sizing, I
    Griffiths, D
    Zafari, M
    Benjamin, CD
    Meier, W
    Mackay, F
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (03) : 867 - 878
  • [8] Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95
    Chinnaiyan, AM
    ORourke, K
    Yu, GL
    Lyons, RH
    Garg, M
    Duan, DR
    Xing, L
    Gentz, R
    Ni, J
    Dixit, VM
    [J]. SCIENCE, 1996, 274 (5289) : 990 - 992
  • [9] A Lymphotoxin-β-Specific Receptor
    Crowe, Paul D.
    VanArsdale, Todd L.
    Walter, Barbara N.
    Ware, Carl F.
    Hession, Catherine
    Ehrenfels, Barbara
    Browning, Jeffrey L.
    Din, Wenie S.
    Goodwin, Raymond G.
    Smith, Craig A.
    [J]. JOURNAL OF IMMUNOLOGY, 2014, 192 (05) : 2015 - 2018
  • [10] The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain
    Degli-Esposti, MA
    Dougall, WC
    Smolak, PJ
    Waugh, JY
    Smith, CA
    Goodwin, RG
    [J]. IMMUNITY, 1997, 7 (06) : 813 - 820